lurasidone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 23 Diseases   12 Trials   12 Trials   1381 News 


«12...45678910111213141516»
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    [VIRTUAL] Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Pediatric Populations with Bipolar Depression () -  May 15, 2020 - Abstract #ISBD2020ISBD_418;    
    In adults with bipolar depression, TE-mania rates were comparable to pediatric patients in short-term studies of lurasidone 20-60 mg/d (3.7%) and 80-120 mg/d (1.9%) vs. placebo (1.9%); and in long-term studies (1.3%). Conclusions In pediatric patients with bipolar depression, treatment with lurasidone was not associated with an increased risk of TE-mania, a finding consistent with results previously reported for adults treated with lurasidone.
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    [VIRTUAL] Long-Term Efficacy of Lurasidone in Pediatric Bipolar Depression: Response, Remission and Recovery () -  May 15, 2020 - Abstract #ISBD2020ISBD_416;    
    Sustained remission was achieved at weeks 52 and 104 by 37.2% and 57% of patients. Conclusions In children and adolescents with bipolar depression, up to 2 years of treatment with lurasidone was associated with continued improvement in depressive symptoms, resulting in progressively higher rates of response, remission, recovery, and sustained remission.
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    Chronic Lurasidone Treatment in Stress-Based Models of Psychiatric Disorders: From Prevention to Functional Normalization (Americas Hall I & II) -  Apr 17, 2020 - Abstract #SOBP2020SOBP_438;    
    In summary, the activity of lurasidone may be particularly relevant in preventing or counteracting the effects caused by stress, by acting on key vulnerability elements for the etiology of psychiatric disorders. Funding Source: This project was supported by funding from the Italian Ministry of Health (Ricerca Corrente to AC), from the Italian Ministry of University and Research (PRIN 2015SKN9YT and PRIN 2017AY8BP4 to MAR) and PON “Ricerca e Innovazione” PerMedNet (project ARS01_01226 to MAR) as well as by a grant from Sumitomo Dainippon Pharma Co to MAR.
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    [VIRTUAL] Recent Pharmacotherapy Advances in Bipolar Disorder () -  Apr 16, 2020 - Abstract #ASCP2020ASCP_112;    
    Collectively, recent trials point to notable efficacy for some but not all SGAs across phases of bipolar disorder, alongside the need for adequate statistical powering and recognition of possible moderators of treatment outcome in emerging studies using novel agents. Learning Objectives: • To understand the clinical significance of recent clinical pharmacotherapy trial findings using newer second generation antipsychotics across phases of bipolar disorder • To differentiate failed from negative randomized trials and issues of statistical underpowering in recent trials of innovative compounds for bipolar depression
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    Journal:  Lurasidone-Induced Delirious Mania. (Pubmed Central) -  Apr 10, 2020   
    The 1.5 mg/d dose of cariprazine evidenced a better benefit-risk profile than the 3.0 mg/d dose of cariprazine. No abstract available
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    Lurasidone in Adolescents with Schizophrenia: Remission and Recovery during 2 Years of Open-Label Treatment (Spadolini - Ground Floor) -  Apr 4, 2020 - Abstract #SIRS2020SIRS_1337;    
    A total of 78 patients (28.8%) met sustained recovery criteria, the mean time to the earliest sustained recovery was 88.8 weeks. Discussion For adolescents with schizophrenia, long-term treatment with lurasidone was associated with continued improvement in psychotic symptoms, resulting in progressively higher rates of remission and recovery over a two year period.
  • ||||||||||  The Dopamine (D1) Positive Allosteric modulator, DETQ, Restored Cognitive Performance and Social Interaction in Sub-Chronic Phencyclidine (PCP)-Treated Mice (Spadolini - Ground Floor) -  Apr 4, 2020 - Abstract #SIRS2020SIRS_1268;    
    P1
    LY3154207, a novel DA D1 positive allosteric modulator (D1PAM) is currently in phase 2 development for Lewy Body Dementias (NCT02603861)...Sub-effective doses (SEDs) of DETQ and the AAPD olanzapine, or SED-DETQ + the ACh esterase inhibitor, rivastigmine, reversed the NOR deficit...Clozapine, but not lurasidone, rescued SI in the sc-PCP+CUS mice...The blockade of its efficacy by gabazine, and haloperidol, and the dialysis data, indicate the importance of D1/D2 effects on adenylate cyclase, and the contribution of GABAAR stimulation, to the efficacy of DETQ. Overall, these data support future studies with D1PAM in a range of neuropsychiatric disorders, including schizophrenia.
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    Journal:  Lurasidone-induced anemia: Is there a need for hematological monitoring? (Pubmed Central) -  Mar 14, 2020   
    We present two cases of schizophrenia, treated with lurasidone developing anemia after variable period of treatment and reverting after stopping lurasidone. These cases emphasize the timely monitoring of blood parameters for prevention or early detection of anemia in patients treated with lurasidone.
  • ||||||||||  aripiprazole / Generic mfg., Latuda (lurasidone oral) / Sumitomo Dainippon, ziprasidone / Generic mfg.
    [VIRTUAL] TRENDS IN ATYPICAL ANTIPSYCHOTIC MEDICATION USE IN US ADULTS () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_288;    
    The results of this study can be used to inform prescribing behavior, clinical decision-making processes, and to predictively model future trends in atypical antipsychotic use. Further research should be conducted to assess the trends in institutionalized populations within the US as these patients have a higher risk of atypical antipsychotic exposure.
  • ||||||||||  Journal:  Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression. (Pubmed Central) -  Feb 27, 2020   
    Appropriate atypical antipsychotic included aripiprazole, clozapine, or quetiapine...However, patients who were taking levodopa (OR=0.62, 95% CI: 0.57-0.67), dopamine agonists (OR=0.90, 95% CI: 0.82-0.98), Catechol-O-methyltransferase (COMT) inhibitors (OR=0.77, 95% CI: 0.68-0.86), Monoamine Oxidase (MAO) inhibitors type B (OR=0.72, 95% CI: 0.60-0.86), or amantadine (OR=0.84, 95% CI: 0.71-0.98) were less likely to receive inappropriate antipsychotics...Various socio-demographics and clinical factors were associated with inappropriate antipsychotic use in older patients with PD. Concerted efforts are needed to reduce inappropriate atypical antipsychotic use among PD patients.
  • ||||||||||  lithium / Generic mfg., Latuda (lurasidone oral) / Sumitomo Dainippon
    [VIRTUAL] Lithium toxicity following sleeve gastrectomy (All Screens in Poster Area) -  Feb 20, 2020 - Abstract #EPA2020EPA_1093;    
    The pathophysiology of lithium toxicity after bariatric surgery, particularly after restrictive procedures, remains unclear. We suggest that therapeutic drug monitoring be performed regularly for patients on lithium after bariatric surgery to prevent toxicity.
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    Review, Journal:  Evaluating lurasidone as a treatment option for bipolar disorder. (Pubmed Central) -  Feb 7, 2020   
    The number needed to treat (NNT) for response with monotherapy was 5 (for both lower and higher dose groups), and for remission was 6 and 7 (for lower dose and higher dose groups, respectively); the NNT for adjunctive therapy was 7. It has not demonstrated efficacy in relapse prevention when added to a mood stabilizer but is safe in combination with other medications.
  • ||||||||||  lurasidone / Generic mfg.
    Trial completion:  A Study of Lurasidone HCl in Subjects With Schizophrenia (clinicaltrials.gov) -  Feb 5, 2020   
    P4,  N=54, Completed, 
    It has not demonstrated efficacy in relapse prevention when added to a mood stabilizer but is safe in combination with other medications. Recruiting --> Completed
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    Journal:  Lurasidone-Induced Mania. (Pubmed Central) -  Jan 30, 2020   
    The current study was inconclusive regarding the efficacy of lurasidone in schizophrenia but further confirmed its safety and tolerability. No abstract available
  • ||||||||||  Comparison of Newer Second Generation Antipsychotics (SGAs) in Regards to Metabolic Profile () -  Jan 21, 2020 - Abstract #AAN2020AAN_3093;    
    Although some weight gain was seen with the newer SGAs, all demonstrated a more favorable metabolic profile compared to olanzapine. Regular monitoring of weight and other metabolic parameters remains an important component of the care plan for patients being treated with these medications.
  • ||||||||||  lurasidone / Generic mfg.
    Trial completion:  18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder (clinicaltrials.gov) -  Jan 18, 2020   
    P4,  N=1, Completed, 
    Regular monitoring of weight and other metabolic parameters remains an important component of the care plan for patients being treated with these medications. Recruiting --> Completed
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    The Cogstate Schizophrenia Battery (CSB) as a Co-Primary Outcome for Trials in Cognitive Impairment Associated with Schizophrenia (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_984;    
    Ability to detect change in cognition in CIAS was evident in several trials, including studies demonstrating ability to detect improvement associated with amphetamine and lurasidone, as well as a longitudinal association with improvement in functional capacity...Discussion The CSB is a well characterized, reliable and valid assessment of cognition, suitable for use as a co-primary outcome in clinical trials of CIAS. It has reduced patient and trial burden and excellent cross-cultural adaptability.
  • ||||||||||  7% Weight Change Associated With Antipsychotics: A Meta-Analysis (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_936;    
    Olanzapine (29.5%) and lurasidone (7.4%) resulted in respectively the highest and lowest CRWG at >38 weeks of treatment...CRWL occurred with all antipsychotic drugs; at 6-16 weeks aripiprazole (7.9%) and ziprasidone (7.1%) had CRWL similar to placebo (8.7%)...More future research is needed on long-term weight effects on both CRWG and CRWL to give a clear overview on the ‘real’ effects on weight, as the majority of studies had a duration of less than 26 weeks. Furthermore, more research is needed on the long-term dose-response relationship in CRWG, as this could prove to be a method for managing weight in some patients.
  • ||||||||||  Balancing Effects with Side-Effects: Examining Comparative Metabolic Consequences of 18 Antipsychotics in Treatment of Schizophrenia Using Network Meta-Analysis (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_816;    
    According to our NMAs, mean differences for weight-gain compared to placebo ranged from -0.23 (95% CI: -0.83, 0.36) for best (haloperidol) to +3.01kg (1.78, 4.24) for worst (clozapine); for BMI from -0.25 (-0.68, 0.17) for best (haloperidol) to +1.07kg/m2 (0.90, 1.25) for worst (olanzapine); for total-cholesterol from -0.09 (-0.24, 0.07) for best (cariprazine) to +0.56mmol/L (0.26, 0.86) for worst (clozapine); for LDL-cholesterol from -0.13 (-0.21, -0.05) for best (cariprazine) to +0.20mmol/L (0.14, 0.26) for worst (olanzapine); for HDL-cholesterol from +0.05 (0.00, 0.10) for best (brexpiprazole) to -0.10mmol/L (-0.33, 0.14) for worst (amisulpride); for triglycerides from -0.01 (-0.10, 0.08) for best (brexpiprazole) to +0.98mmol/L (0.48, 1.49) for worst (clozapine); for glucose from -0.29 (-0.55, -0.03) for best (lurasidone) to 1.05mmol/L (0.41, 1.70) for worst (clozapine)...By contrast, compared with placebo, lurasidone and cariprazine respectively reduce fasting glucose and LDL-cholesterol, while aripiprazole and brexpiprazole increase HDL-cholesterol...Considering the increased prevalence of metabolic syndrome, cardiovascular disease, and cardiovascular mortality in schizophrenia, these data may be used to inform antipsychotic-prescribing, especially in those at-risk groups we have identified. However, clinical decisions to preferentially use an antipsychotic with fewer metabolic side effects should consider that clinical improvement appears to be associated with development of these side effects.
  • ||||||||||  risperidone / Generic mfg., Egis, Latuda (lurasidone oral) / Sumitomo Dainippon
    Model-Based Analysis of Effects of Lurasidone on Prolactin in Schizophrenia Patients (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_449;    
    The elevation of PRL in male subjects was significantly lower than in female subjects. Discussion Despite the potential limitation of simulation model, lurasidone might be a valuable option for schizophrenia patients, especially for female patients, to minimize PRL related side effects, which might improve the patients' compliance and quality of life.
  • ||||||||||  Latuda (lurasidone oral) / Sumitomo Dainippon
    Long-term changes of miRNA30a following exposure to prenatal stress: modulatory effects of lurasidone treatment during adolescence. (Spadolini - Ground Floor) -  Jan 17, 2020 - Abstract #SIRS2020SIRS_283;    
    Furthermore, we show that chronic lurasidone treatment was able to prevent some of the changes produced by PNS, with a major effect on miRNA30a levels as well as on its target genes LIMK, MAP2K2 and PIK3CA. These effects may be particularly relevant in preventing some molecular alterations induced by ELS exposure, known to be involved in the development of stress-related psychiatric disorders, and thus be useful in minimizing the individual risk of vulnerability.